BioinvestGPT ApS · Research use only

BVCT solutions

19 case studies and newsletters from BioinvestGPT, each featuring a unique BVCT capability, from Reuters-reported virtual trials of high-profile readouts, atom-level clinical benefit prediction, patient-data-free calls made before the first patient enrols, first-in-class mechanism calls that look past the biomarker, any-phase calls spanning Phase 1/2 and Phase 3, pipeline-level GO/NO-GO calls, portfolio-wide NO-GO calls shared before the readouts, clinical benefit prediction from mRNA sequence, Phase 3 outcome calls made well before the readout, PFS/OS discordance calls, overall-survival calls in HER2-positive cancers, sealed calls on the year’s most-watched readouts, variant-level clinical derisking before wet-lab spend, verification of AI co-scientist hypotheses, in vivo CAR-T design simulation, ADC design and biomarker discovery, clinical prediction from the genome alone, mathematics-based hazard-ratio prediction, to a self-service GO/NO-GO web app. Each cited prediction links to its trial page, with the prediction date, the recorded calls and the readout classification.

In the news

Pipeline and asset case studies

Calls ahead of readouts

Platform and perspective

  • Platform · Genetic variants · 8 Jul 2026Clinically Derisk Every Genetic Variant Before Preclinical Spend.BVCT simulates a Phase-III effect size vs standard of care for each candidate variant, patient-data-free. VERVE-101 was called FAILURE 12 days before data.3 dashboard predictions cited
  • Platform · BVCT and pharma AI co-scientists · 2 Jun 2026The Clinical Derisking Layer for Every Pharma AI Co-Scientist.How BVCT scores AI co-scientist hypotheses by simulated Phase III effect size vs standard of care, with mavacamten (No. 1959) and aficamten (No. 2094).2 dashboard predictions cited
  • Decisive clinical advantage · In vivo CAR-T design · 23 Apr 2026The Clinical GPS of in vivo CAR-T DesignBVCT simulates in vivo CAR-T design features, from fusogens to payload decay, to forecast effect size (HR, ORR) against a competitor in vivo CAR-T or SoC.
  • Decisive clinical advantage · ADC designThe Clinical GPS of BeatSoC ADC Drug Design and Biomarker DiscoveryBVCT simulates how each ADC design and patient stratification parameter changes the PFS/OS hazard ratio vs standard of care, without retrospective RWD.
  • Patient-Data-Free · TRL-9 · Deployed · 3 May 2026The Genome Is Enough — A TRL-9 Existence ProofBVCT predicts the clinical-benefit hazard ratio of any candidate drug versus standard of care from the genome, with no patient data ingested.
  • Perspective · Mathematics, not data · 4 May 2026Mathematics is EnoughWhy BVCT predicts Phase-3 hazard ratios from mathematics and the genome, with no patient data, where statistical AI is structurally blind.
  • BioinvestGPT · BVCT web app · Introduction · 22 Apr 2026Gain clinical foresight before every decision.The BVCT web app: predicted clinical effect sizes vs standard of care, a causal knowledge graph and virtual clinical trials for every GO/NO-GO decision.